Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy B.H.N. Ltd. reports developments in Additively Manufactured Electronics, quantum connectivity and its medical technology portfolio. Company updates focus on AME system orders and deployments, QTREX-branded cryogenic interconnect work for superconducting quantum systems, customer activity with research, defense and technology organizations, and leadership or strategic-direction announcements.
The company's medical technology context includes respiratory support and blood monitoring platforms, including INSPIRA ART, INSPIRA ART100 and the HYLA Blood Sensor, while recent communications emphasize a dedicated medical business unit alongside the AME and quantum connectivity strategy.
Aegis Capital Corp. acted as Sole Bookrunner for a $16.0 million Initial Public Offering of Common Units for Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW). The company is focused on respiratory treatments with its innovative Augmented Respiration Technology that stabilizes oxygen saturation levels, allowing patients to remain awake during treatment.
This technology aims to reduce reliance on mechanical ventilation, which is often invasive and risky.
Inspira Technologies, a leader in respiratory medical technology, announced a significant development in preventing blood clotting with its Augmented Respiration Technology (ART) system. Collaborating with Ben-Gurion University, the company aims to enhance the ART system by integrating a platform that utilizes polymeric microbubbles to release oxygen on demand. This innovation seeks to improve patient outcomes by potentially eliminating the need for anticoagulants, which carry risks of life-threatening bleeding. The ART system, still in development, aims to stabilize patient oxygen levels without mechanical ventilation.
Inspira Technologies OXY B.H.N. Ltd has successfully closed its initial public offering (IPO) of 2,909,091 units at a price of $5.51 per unit, generating approximately $16 million in gross proceeds. Each unit includes one ordinary share and one warrant. The company has granted Aegis Capital Corp. a 45-day option for additional shares and warrants. The shares and warrants are now trading on Nasdaq under symbols IINN and IINNW respectively. Notably, Inspira's Augmented Respiration Technology is still pending FDA approval and human testing.
Inspira Technologies OXY B.H.N. Ltd announced the pricing of its initial public offering (IPO) of 2,909,091 common units, priced at $5.51 each, comprising one ordinary share and one warrant per unit. The offering is expected to raise $16 million in gross proceeds and is set to close on July 16, 2021, subject to customary conditions. Additionally, Aegis Capital Corp. has a 45-day option to purchase up to 15% more common units to cover over-allotments. Trading on Nasdaq is expected to begin on July 14, 2021 under the symbols IINN and IINNW.